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Tuberculosis in the United States is evolving in nearly all respects-epidemiology, diagnosis,
treatment, and prophylaxis. Today a relatively larger segment ofthe population has predisposing
factors toinfection with tuberculosis. There is agreater percentageofpeoplewhoareelderly, who
have immigrated from countries endemic for tuberculosis, or who are immunosuppressed due to
medications necessary for other conditions, because ofmalignancies, or because ofinfection with
HIV. Skin test classifications have been revised togive different meanings to different-sized areas
ofinduration at the injection sitefor defined populations. More sensitive, more specific, and faster
diagnostic laboratory tests for tuberculosis are being developed. Short-course chemotherapy of
from six to nine months is now accepted as standard treatment, regardless ofexactly which ofthe
proven regimens of antibiotics or accepted lengths of therapy is used. Patient compliance is
improved with the shorter courses both for treatment and forprophylaxis. Better compliance with
therapy results in better treatment outcomes ofinfections with Mycobacterium tuberculosis.
EPIDEMIOLOGY
Since the beginning of the twentieth century, tuberculosis has declined from being
the most common cause of death to a relatively uncommon disease [1-3]. Between
1953 and 1984, the number of cases of tuberculosis reported annually in the United
States decreased by 74 percent from 84,304, to 22,255 cases per year, and the annual
risk of tuberculosis decreased from 53.0 to 9.4 per 100,000 population [4]. Although
the incidence has declined in developed countries, the World Health Organization
estimates more than ten million cases and two to three million deaths due to
tuberculosis annually [5]. Others estimate that there are at least one billion persons
infected with M. tuberculosis in the world [6], although, for most, infection is
detectable only by tuberculin skin test positivity.
UnitedStates
From 1968 through 1978, the average annual decrease in tuberculosis cases in the
United States was about 5.9 percent. From 1979 through 1981, the average annual
decline was only 1.4 percent. This break in the previous downward trend was due
primarily to the influx of Southeast Asian refugees and immigrants from Mexico and
the Caribbean [2,7]. An average decline of 6.7 percent from 1982 through 1984 (Fig.
1) indicated resumption of the downward trend [8-10], and, as recently as 1984, it
looked as though the national objective ofeight cases per 100,000 population per year
by 1990 would be met; however, a decline ofonly 0.2 percent (22,255 to 22,201 cases)
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FIG. 1. Numbers of reported tuberculosis cases in the United States from 1981 to 1987. Estimated
number ofaccumulated excess cases from 1985 through 1987. Reproduced from [4].
in 1985 [4,11] heralded another slowing ofthis trend (Fig. 1). In 1986, 22,768 reported
tuberculosis cases represented an increase of 2.6 percent. If the downward trend
observed between 1981 and 1984 had continued through 1986,4,832 fewer cases would
have been expected. Instead, 567 more cases were actually reported [12]. Previous
increases were due to changes in reporting criteria (1963 and 1975) or to a sudden
influx ofrefugees (1980). 1986 represented the first substantial increase in indigenous
tuberculosis since 1953, when uniform national reporting was fully implemented.
The number ofU.S. tuberculosis cases increased for adults ofall racial and ethnic
groups except American Indians and Alaskan natives. Cases in children less than five
years of age actually decreased substantially. Childhood cases strongly suggest trans-
mission has occurred; thus a decrease in cases of children in the face of an overall
increase in total cases signifies that these excess cases may be due to reactivation of
latent tuberculous infection rather than increased transmission. Although recent
increases in tuberculosis have been reported from many localities, New York experi-
enced the most marked increase. The largest percentage increase was among Hispan-
ics, but the most dramatic increase in numberofcases was among non-Hispanic blacks,
in whom reported cases almost doubled from 1980 to 1987, primarily in the 30- to
39-year-old age group. In fact, in 1987, there were more cases of tuberculosis among
non-Hispanic blacks in the United States than among all non-Hispanic whites [4].
Connecticut
In Connecticut, there were 6.3 percent fewer cases of tuberculosis in 1987
compared to 1986, but this was the same rate reported in 1985, continuing a stable
trend that began here in 1983. The overall incidence was 5.0 cases per 100,000
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FIG. 2. Continuous rise in the ratio ofannual risk for tuberculosis among non-whites compared to whites
from 1953 to 1987. Reproduced from [4].
population, compared to the high of 18.0 in Hawaii and to the low of0.6 in Wyoming.
Connecticut ranked thirty-third in the nation in case rate. In the four target outreach
cities-Bridgeport, Hartford, New Haven, and Stamford-cases decreased from 88
cases in 1986 to 84 cases in 1987. In New Haven, however, the case rate increased from
31 to 36 cases, to exceed the average case rate for United States cities with populations
over 250,000 by 46 percent. The number of cases in the five Conneticut cities with
populations greater than 100,000 decreased by 4 percent. Although they contain only
19 percent of the state's population, they were responsible for 55 percent of statewide
cases. Most of these cases were in the 25- to 34-year-old age group and may be
AIDS-related. Other contributing factors may be preferential immigration to urban
areas, overcrowding, especially among the homeless, and inadequate staffing to carry
out intensive tuberculosis prevention programs in urban areas [13].
RISK FACTORS
Racial
For over 30 years, the decrease in cases was smaller among non-whites than whites,
resulting in a continuous rise in the ratio of annual risk of tuberculosis among
non-whites to whites (Fig. 2). Based on 1987 statistics, the risk compared to non-
Hispanic whites is 11.2 times for Asians and Pacific Islanders, 6.4 times for non-
Hispanic blacks, 4.7 times forAmerican Indians and Alaskan natives, and 4.3 times for
Hispanics [4]. Two recent papers [14,15] looked at racial differences in susceptibility
to infection with M. tuberculosis. In Arkansas, Stead et al. found the prevalence of
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tuberculosis in black residents of nursing homes was twice as high as in whites [14].
They performed skin tests on all residents upon entry into racially integrated nursing
homes and found that 25,398 were initially skin test-negative. Ofthese, 13.8 percent of
the black subjects converted their skin tests, while only 7.2 percent of the whites had
evidence of new infection. Blacks were infected moreoften regardless ofthe raceofthe
source patient. A single white resident with a positive sputum smear typically infected
17.4 percent of the blacks and 11.7 percent of the whites (p < 0.001). A comparable
black resident typically infected 12.4 percent of the blacks and 7.7 percent of the
whites (p < 0.001). Interestingly, upon converting their skin tests, there was no racial
difference in the percentage of residents who, in the absence of preventive therapy,
were later found to have clinical tuberculosis-I 1.5 percent ofblack converters versus
10.6 percent of white converters. Data from three outbreaks in two different prisons
also showed that blacks were about twice as likely to become infected. The authors
concluded from this study that blacks are more readily infected with M. tuberculosis,
but that this susceptibility varies independently of factors governing progression to
clinical disease.
The second study [15] looked in vitro for a cellular basis of the long-held belief
that blacks are more susceptible to tuberculosis than whites. Using monocyte-derived
macrophages from blacks and whites, the investigators found that black donor phago-
cytes killed more bacilli during phagocytosis than white donor phagocytes, but bacilli
grew consistently and significantly faster in successfully infected macrophages from
black donors than from white. The results of the above two studies support the
impression that blacks are more likely to become infected with M. tuberculosis,
perhaps partiallyexplaining their slower decrease in incidence over the years and their
marked increase relative to other racial groups with the recent rise in number ofcases.
AIDS
The rapid increase in New York cases occurred almost exclusively in the 20- to
54-year-old age group, suggesting that endogenous latent tuberculous infection was
being reactivated because of some factor particularly prevalent in these young adults
[4]. Comparison ofcitywide registries on AIDS and tuberculosis cases revealed that 5
percent ofthe first 5,000 adult and adolescent patients with AIDS also had tuberculo-
sis. Fifty-seven percent oftuberculosis/AIDS patients were intravenous drug abusers,
whereas only 34 percent of AIDS patients without tuberculosis had this risk factor
[16]. Fifty-three percent ofa groupofmalepatients between ages 25 and 44 years with
tuberculosis werepositiveforhuman immunodeficiencyvirus (HIV) antibody. In Dade
County, Florida, 31 percent of consecutively tested patients with tuberculosis were
HIV-positive [12], and in San Francisco, California, 28 percent of a study group with
tuberculosis were positive by serologic tests for HIV infection [17]. Other studies
[18,19] have reported from 20 percent to 60 percent ofAIDS patients with tuberculo-
sis. In some geographic areas, tuberculosis may be diagnosed before the patient is
known or even suspected to have AIDS. In a prospectivestudy of520 intravenous drug
users, Selwyn et al. [20] clearly demonstrated that although there was littledifference
in prevalence and incidence ofinfection with M. tuberculosis among HIV-seropositive
and HIV-seronegative individuals, only HIV-seropositive subjects with positive tuber-
culin skin tests had increased risk of developing active tuberculosis within two years.
Thus HIV infection seems to be a significant risk factor for developing tuberculosis,
especially among some subgroups, just as compromised immunity due to other
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disorders is associated with increased risk ofdeveloping clinically apparent tuberculo-
sis [21].
Among the infections afflicting AIDS patients, tuberculosis is a uniqueopportunistic
pathogen because untreated M. tuberculosis can be transmitted to otherwise healthy
individuals, and good, safe, effective therapy exists for tuberculosis. Although early
reports suggested AIDS patients with active disease might present with clinically
atypical disease [22-26], a more recent study [17] indicated they will have clinically
typical tuberculosis that responds well to standard therapy with no greater associated
drug toxicity. The treatment for active tuberculosis in HIV-infected persons should
include at least three drugs for the first two months. In addition, total duration of
treatment should be a minimum of nine months and for at least six months after
documented culture conversion [27]. Close monitoring should follow completion of
therapy.
The Centers for Disease Control now recommends that a tuberculin skin test be
performed on all HIV-infected individuals [27]. Although a skin test may be negative
because ofanergy, a positive skin test is meaningful. Because they are at increased risk
for developing clinical tuberculosis, HIV-infected persons who have or have had in the
past a positive tuberculin skin test should receive preventive therapy with isoniazid
after active tuberculosis is ruled out regardless ofage. Alternatively, HIV testing ofall
individuals with tuberculosis should be considered [16].
Age
The elderly are likely to present with atypical symptoms oftuberculosis. As immune
systems decline with aging, senior citizens with healed tuberculous lesions are likely to
experience recrudescence ofdisease. When diabetes, malignancy, corticosteroid ther-
apy, or other debilitating problems are present, relapse rates are even higher. Older
citizens may lose former immunity and develop "primary" tuberculosis a second time.
Clinical and roentgenographic presentations of initial infections tend to be atypical
[28,29]. Thus thereexists a potential forprolonged exposure while a lengthydiagnostic
work-up is pursued or inappropriate medication is administered. Some investigators
[29] feel that nursing home transmission oftuberculosis is much more common than is
presently appreciated.
Other
Similar to HIV-infected individuals, persons taking immunosuppressive medication
are more likely to develop active tuberculosis [4]. Others are at increased risk for
tuberculosis because ofdiseases such as end-stage renal disease requiring maintenance
on chronic hemodialysis [30], diabetes, hemophilia, and malnourishment [4]. Persons
who are heavy smokers, or who have silicosis, carcinoma of the head or neck, or who
have undergonejejunoileal bypass or gastrectomy (or who have achlorhydria for other
reasons) have increased risk. Also at risk are persons unlikely to seek medical care or
unlikely to comply with treatment regimens (especially alcoholics and drug abusers)
[2], North American Indians, inhabitants of ethnic ghettos, prisoners, residents of
institutions for the mentally and physically handicapped [31], and immigrants from
places with a high prevalence oftuberculosis [4].
TRANSMISSION
Tuberculosis is not, however, an easily transmitted disease [2]. Generally, house-
hold contacts of cases rather than casual contacts become infected. Of those exposed,
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only 3 to 5 percent get progressive tuberculosis. The organism is spread from person to
person via aerosolized droplets of respiratory secretions that are one to five microme-
ters in diameter, too small to bestopped by masks. Dropletsjustcoughed out arelarger,
then decrease in size with time and dessication. Thus, to stop droplets, it is probably
wiser to mask the patient rather than to mask those exposed to him or her. Larger
inhaled particles settle in the upper airways and are eliminated via thegastrointestinal
tract. Droplets smaller than one micrometer are exhaled. A particle of the right size
must be inhaled, reach pulmonary alveolar membranes, and multiply to cause a
primary, nonspecific pneumonitis, usually in the lower lobes. A "primary pulmonary
complex" composed of a peripheral pulmonary infiltrate plus enlarged lymph nodes to
which the area drains may develop [311. Over the ensuing weeks, skin test sensitization
and resistance to exogenous reinfection develop. Organisms disseminate hematoge-
nously and lymphatogenously to plant occult seeds of mycobacteria in distant organs
and other parts of the lungs. They are phagocytosed, but are not necessarily killed,
resulting in granuloma formation, although occasionally dissemination with massive
tissue destruction, as seen in miliary tuberculosis, may occur.
PATHOGENESIS
M. tuberculosis is opsonized by the alternative complement pathway for ingestion
by monocytes via linking ofmycobacteria-bound C3 tocomplement receptors CR1 and
CR3 [32]. This process is important in the pathogenesis of M. tuberculosis, since
physiologic functioning ofhost immunity (both humoral and cell-mediated systems) is
subverted by the organism to facilitate entry into cells it will live in, sometimes for
decades. Thefirst phagocyticcell to arrive at the siteoftheinfection is the polymorpho-
nuclear leukocyte. Neutrophils are capable of ingesting and killing the tubercle
bacillus [33]. The organisms survive intracellularly for years, but the short life of
neutrophils makes them unlikely to harbor dormant infections. In fact, mycobacteria
hide in macrophages, somehow preventing fusion of phagosomes and lysosomes and
avoiding the usually lethal consequences of phagosome-lysosome fusion. Exposure to
specific antisera does not destroy infectivity, and, when ingested by macrophages,
antiserum-treated bacilli continue to multiply. Replication proceeds despite the fact
that antibody-coated mycobacteria permit phagosome-lysosome fusion! It appears that
this intracellular parasite has evolved not one, but at least two ways of evading the
consequences oflysosomal fusion (reviewed in [34]). The second mechanism probably
is related to the ability of one or more mycobacterial products to interact with
lysosomal structures essential for lysosomal acidification. Somehow these elements
inhibit lysosomal acidification and provide a safe haven for the mycobacteria.
Phagocytosed mycobacteria may lie dormant within granulomas for years and
never cause problems for the life of the host. A positive tuberculin skin test reaction
may be the only remaining clue to the infection. Alternatively, after years or even
decades, the granulomas may break down, and chronic secondary tuberculosis may
emerge, usually involving the lungs. Extrapulmonary disease is seen to occur in lymph
nodes, pleura, pericardium, peritoneum, intestines, kidneys, adrenals, genitalia, bones,
joints, or meninges. One study [35] reported that extrapulmonary tuberculosis ac-
counted for 37 percent of all new cases of tuberculous infection identified during an
11-year period at Waterbury Hospital Health Center, a 552-bed, university-affiliated,
community teaching hosptal in Connecticut.
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TABLE 1
Intrepretation of Intracutaneous Mantouxa Test
1. A reaction of5 millimeters or more ofindurationb is classified as positive in the following groups:
a. Persons who have had close recent contact with tuberculosis
b. Persons who have chest radiographs consistent with tuberculosis
c. Immunosuppressed persons
2. A reaction of 10millimeters or more ofinduration' is classified as positive in persons who do not meet
the above criteria but who have other risk factors for tuberculosis. These include:
a. Foreign-born persons from high-prevalence countries in Asia, Africa, and Latin America
b. Users ofintravenous drugs
c. Homeless individuals
d. Residents ofnursing homes
e. Residents ofcorrectional institutions
f. Persons with factors which increase the risk oftuberculosis, such as silicosis, diabetes mellitus, immu-
nosuppressive therapy, some hematologic and reticuloendothelial disease, and clinical situations asso-
ciated with substantial rapid weight loss or undernutrition
3. A reaction of 15 millimeters or more ofindurationb is classified as positive in all other perons.
aIntracutaneous with 5TU tuberculin PPD
bReactions below the indicated size in each category are considered negative.
DIAGNOSIS
Tuberculosis is a systemic disease with protean manifestations. Direction ofdiagnos-
tic studies will be dictated by data obtained from the history, physical examination,
roentgenograms, and skin testing.
Skin Testing
Information used to determine whether or not an individual is infected with
mycobacteria include results ofa tuberculin skin test. The Centers for Disease Control
has recently changed the classification of tuberculin skin test reactors which will be
contained in the revision of"Diagnostic Standards and Classification ofTuberculosis"
to be published as joint American Thoracic Society/Centers for Disease Control
statements in the American Review ofRespiratory Diseases [36]. The new classifica-
tion says that reactions to the intracutaneous Mantoux test (with 5TU tuberculin
PPD) should be interpreted as follows (Table 1): A reaction of5millimetersormoreof
induration is classified as positive in persons who have recently been in contact with
tuberculosis, have chest radiographs consistent with tuberculosis, or who are immuno-
suppressed. A reaction of 10 millimeters or more ofinduration is classified as positive
in persons who do not meet the above criteria but who have other risk factors for
tuberculosis, such as foreign-born persons from high-prevalance countries, intravenous
drug users, homeless individuals, residents ofnursing homes or ofcorrectional institu-
tions, and persons with factors that increase the risk of tuberculosis, such as silicosis,
diabetes mellitus, immunosuppresive therapy, some hematologic and reticuloendothe-
lial disease, and clinical situations associated with substantial rapid weight loss or
undernutrition. A reaction of 15 millimeters or more of induration is classified as
positive in all other persons. Reactions below the indicated size in each category are
considered negative. Although these recommendations appear to be more complicated
that those of the past, there are scientific and ethical reasons for making them. The
scientific reasons consider factors that influence the sensitivity and specificity of the
test and the estimated prevalence of tuberculosis infection in the population tested.
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Ethical considerations include the consequences ofmisclassifying someone as infected
or not infected [36]. Of particular concern is the potential spread of tuberculosis by
someone who develops active pulmonary tuberculosis all the while believing himselfor
herselffree ofinfection based on skin test interpretation.
Stains
To reach a definitive diagnosis, one must demonstrate M. tuberculosis by staining
techniques and microscopy and/or culture. Acid-fast staining, such as Kinyoun carbol
fuchsin, is quick and inexpensive, but not specific. Other mycobacteria, nocardia, and
some legionella are also acid-fast. Some laboratories rapidly screen sputum smears
using acid-fast fluorescent dyes that attach to mycobacteria; ultraviolet light activates
the dye to produce fluorescence. The sensitivity and specificity of carbol fuchsin and
fluorochrome stains are comparable, but examination of fluorochrome-stained organ-
isms is much more efficient. While carbol fuchsin stains must be examined using the
100x oil immersion objective, fluorochrome-stained samples are examined with a 25x
objective [37]. There must be about 1 x 104 organisms/ml sputum to detect their
presence on smear. With presently available technology, it is important to obtain
diagnostic studies early in the disease, preferably before beginning treatment. In the
presence ofisoniazid therapy alone, the number oforganisms drops one log per day the
first two to three days. The rate ofdecline is even greater ifrifampin is included in the
treatment. Organisms not killed arelesshardyand less likely to be recovered byculture
on artificial media.
Cultures
Ideally, the organism is recovered by culture, allowing distinction ofM. tuberculosis
from other mycobacteria and testing of the isolate for drug susceptibility. Culture is
considerably more sensitive than smear techniques but much more expensive and
time-consuming. Some laboratories use a BACTEC TB System [38] that may reduce
the time required to grow mycobacteria from an average ofthree weeks to a matter of
days. The BACTEC system uses a liquid medium containing a growth-promoting
substance, polyoxyethylene stearate, and also containing polymyxin B, amphotericin
B, nalidixic acid, trimethoprim, and azlocillin to suppress growth of contaminating
microorganisms. The system detects mycobacterial growth by measuring 14Co2 re-
leased intotheatmosphere above the medium as a result ofmetabolism ofa 14C-labeled
substrate in the media. Although cultures may not be considered negative for growth
until they have been observed for at least three weeks, some will show evidence of
mycobacterial metabolism in about a week or ten days. Drug susceptibility testing can
also be done, as well as tests to differentiate the tuberculosis complex from other
mycobacteria. All these techniques are complementary. A positive acid-fast smear
considered with other data may allow one to initiate reasonable therapy while waiting
for the results ofcultures and sensitivity testing.
Others
Other laboratory detection techniques have been used experimentally. Measurement
of cerebrospinal fluid adenosine deaminase activity to detect meningeal tuberculosis
[39] or detection of tuberculostearic acid in sputum by gas chromatography-mass
spectrometry [40] are examples. More recently, DNA amplification by polymerase
chain reaction, using probes specific for M. tuberculosis, has been investigated as a
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diagnostic technique [411. The probes used are particularly interesting because the
probe DNA sequence is repeated several times in the bacterial chromosome. These
studies may provide a basis for an assay to detect easily very small numbers of M.
tuberculosis directly in clinical specimen.
Attempts todevelop a reliable serologic test for infection with M. tuberculosis began
shortly after Koch identified the tubercle bacillus. Of late, investigators have focused
on developing an enzyme-linked immunosorbent assay for testing serum. As yet, no
serologic test with sufficiently high sensitivity and specificity has been produced,
although the need for such a technique remains high [42].
TREATMENT
History
It is now clear that shorter courses of chemotherapy are as successful as more
traditional longer courses of antibiotics. Effective chemotherapy began in the mid-
1940s, with the discovery of streptomycin. In the early 1950s, a second bactericidal
drug, isoniazid, was discovered. Later, p-aminosalicylic acid and ethambutol were
available. In the late 1960s, rifampin, a third bactericidal drug, was introduced. Over
the next decade, use of isoniazid and rifampin in combination made it possible to
shorten therapy from the conventional 18 to 24 months. Complementary bactericidal
activities of these two drugs made it possible actually to sterilize tuberculous lesions
[43]. Since Dutt et al. [44] reported in August 1984, their success with a nine-month
course of chemotherapy administered by local practitioners and public health nurses,
experience has proven that treatment for longer periods of time is not necessary for
pulmonary or extrapulmonary [45] tuberculosis.
Effective Treatment Schedules
Two recent publications [46,47] show that as few as six months of therapy is
successful in curing tuberculosis, even when for a significant part of that time
medications are administered only twice weekly. In both studies, the subjects took at
least two bactericidal drugs, isoniazid and rifampin. Two effective, relatively nontoxic,
acceptable treatment schedules emerged from these studies (Table 2). In the work by
Combs et al. [46], patients were selected on the basis ofhaving sputum culture isolates
of M. tuberculosis that were susceptible to the study drugs. About half the subjects
were assigned to the six-month regimen and the other halfto the nine-month regimen.
All patients self-administered isoniazid and rifampin daily for 24 weeks (Table 2
USPHS Tuberculosis Short-Course Chemotherapy). In addition, patients in the
six-month regimen tookpyrazinamide dailyduringthe first eight weeks. Patients in the
six-month regimen had bacteriologic sputum conversion more rapidly than patients on
the nine-month regimen, had similar rates of adverse drug reactions, and similar
relapse rates 96 weeks after completion of therapy. Of importance is the fact that
patients on the six-month regimen had lower noncompliance rates, and a significantly
greater proportion successfully completed therapy. Beginning in 1984, a third treat-
ment regimen was added. Someofthepatients weretreated forsix months with Rifater
(Merrell Dow Research Institute, Cincinnati, OH), a combination tablet ofisoniazid,
rifampin, and pyrazinamide. These patients also had successful outcomes. They
experienced bacteriologic conversion tonegative at a more rapid rate, but they also had
a slightly higher rate of adverse effects. The authors concluded that the six-month
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TABLE 2
Acceptable Treatment Regimens for Tuberculosis
TheDenver Metro CenterRegimen [46]
First two weeks'
Isoniazid, 300 mgb
Rifampin, 600 mg
Pyrazinamide, 1.5 g if s50 kg body weight; 2.0 g if 51 to 74 kg; 2.5 g if >75 kg
Streptomycin, 750 mg if 50 kg body weight; 1.0 g if>50 kg
Week 3 through week 8 (given twice weekly)'
Isoniazid, 15 mg/kg body weight
Rifampin, 600 mg
Pyrazinamide, 3.0 g if -50 kg body weight; 3.5 g if51 to 74 kg; 4 g if 275 kg
Streptomycin, 1.0 g if s50 kg body weight; 1.25 g if 51 to 74 kg; 1.5 g if.75 kg
Week 9 through week 26 (given twice weekly)
Isoniazid, 14 mg/kg body weight
Rifampin, 600 mg
USPHS Tuberculosis Short-Course Chemotherapyd [47]
Nine-month regimen (36weeks)'
Isoniazid, 300 mg
Rifampin, 600 mg
Six-month regimen'
First eight weeks
Isoniazid, 300 mg
Rifampin, 600 mg
Pyrazinamide, 30 mg/kg body weight
Week 9 through week 16
Isoniazid, 300 mg
Rifampin, 600 mg
'Medications given as onedaily dose
blsoniazid, rifampin, and pyrazinamidegiven by mouth; streptomycin given intramuscularly
CIfM. tuberculosis isolates are resistant to isoniazid, change the regimen to rifampin, pyrazinamide, and
streptomycin twice weekly, and ifresistant to streptomycin, give theabove regimen without streptomycin.
dAdd daily ethambutol, 15 mg/kg body weight, ifpatients have a history ofprevious isoniazid therapy or
have emigrated within the past 30 years from a country where a high proportion oftuberculosis patients
havedrug-resistant disease. Adjust medications when results ofsensitivity testing are available.
regimen was similar in effectiveness, toxicity, and acceptability to the nine-month
course for treatment for pulmonary tuberculosis.
Cohn and colleagues [47] studied a 62-dose, six-month regimen (Table 2, Denver
Metro Center Regimen) oftreatment for pulmonary andextrapulmonary tuberculosis.
Patients with known or suspected tuberculosis took isoniazid, rifampin, pyrazinamide,
and streptomycin daily for two weeks. Then these drugs were given in higher doses
twice weekly for six weeks, followed by isoniazid and rifampin twice weekly for 18
weeks, for a total of 62 doses. All therapy was directly observed by a nurse or an
outreach worker. There were no treatment failures among evaluable patients, and only
two patients had relapses of pulmonary tuberculosis. Although the group of patients
with extrapulmonary tuberculosis contained too few patients to state with certainty
that the regimen is effective in treating extrapulmonary tuberculosis, the results are
consistent with other reports ofthe efficacy ofsix- and nine-month treatment regimens
for extrapulmonary tuberculosis [45,48]. No mention is made in this article [45] ofthe
role of surgery in tuberculous osteomyelitis. There is controversy about the benefits of
surgery in Pott's disease, but earlier studies [45] showed enhanced healing when early
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TABLE 3.
Laboratory and Microbiologic Monitoring During Therapy
Before treatment:
1. Three sputum specimens for acid-fast bacilli
2. A complete blood count
3. Liver function tests
4. Uric acid assessment
5. Chest X-ray
Duringtreatment, once each month:
1. One specimen for acid-fast bacilli per month until culture-negative
2. A complete blood count
3. Liver function tests
4. Uric acid assessment
5. Chest X-ray (only after the first month oftherapy)
After the completion oftherapy:
1. One specimen for acid-fast bacilli
2. Chest X-ray
drainage and complete debridement of necrotic tissue were performed in the presence
ofbone destruction and abcess formation.
Monitoring Response and Toxicity
Rapid sterilizing activity of the four drugs used in the initial phase of the Denver
study rendered patients non-infectious more quickly, a characteristic that may be
especially important for noncompliant patients. The regimen was no more toxic than
others. To follow response and toxicity, these authors recommended the following
microbiologic and laboratory monitoring (Table 3): (1) Three sputum specimens for
acid-fast bacilli before treatment, one specimen per month during treatment until
conversion to culture-negativity, and one speciment after completion of therapy; (2) a
complete blood count, liver function tests, and uric acid assessment before treatment
and once monthly during treatment; and (3) a chest roentgenogram before treatment,
at one month, and after the completion of therapy. Others believe the non-
microbiologic laboratory studies need to be performed only if the patient becomes
symptomatic for drug toxicity, especially young, otherwise healthy adults without
impaired liver function.
Resistance
Immigrants who arrive from many geographic areas infected with M. tuberculosis
may bring with them drug-resistant organisms. In developing nations, resistance ofM.
tuberculosis to the major treatment drugs, especially isoniazid and streptomycin, may
occur in 20 percent to 30 percent of new cases. Resistance rates are particularly high
among Hispanic and Asian ethnic groups [2]. Drug sensitivity studies [49] on isolates
ofM. tuberculosis from Indochinese immigrants found resistance to one or moredrugs
in 33 percent of the isolates. Twenty-two percent were resistant to streptomycin, 25
percent to isoniazid, and 3 percent each to rifampin and ethambutol. Fortunately,
primary resistance to rifampin and ethambutol is relatively rare, even in areas where
resistance to other drugs is common. Inclusion of these two drugs in initial treatment
regimens enhances the possibility that the organism will be affected by the regimen.
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PROPHYLAXIS
Antimicrobial Agent and Duration
The regimen for prophylaxis against tuberculosis is less well defined. Isoniazid is the
only drug proven effective for this purpose. Rifampin may be effective but is untested
and expensive and should only be used in extraordinary cases. It is generally accepted
that 300 mg ofisoniazid taken daily for one year with good compliance reduces disease
due to tuberculosis by 90 to 95 percent [50]. Prophylactic treatment for 12 weeks only
slightly reduces active disease, whereas a 24-week regiment produces a 65 percent
reduction [51]. When all patients are considered together, very compliant and less
compliant, one year of therapy with isoniazid improves the protection from overt
tuberculosis by 75 percent. This rate is only slightly better than the 65 percent
reduction achieved with the 24-week course. The American College of Chest Physi-
cians considered the preventive recommendations at the National ACCP Consensus
Conference on tuberculosis [52] in 1985. From this conference came a recommenda-
tion for nine months of daily isoniazid for prophylaxis. It was felt that ultimately the
recommended schedule will be for only six months. Compliance is likely to be superior
in this shorter version of prophylaxis [53,54]. An alternative prophylactic schedule
considered by some would be a short course of medications that include rifampin and
pyrazinamide if they could be produced and sold at prices substantially lower than
their present cost [54].
Even now, if a patient misses more than one month ofisoniazid prophylaxis but has
completed more than six months oftreatment at the timeofhis lapse, consideration for
terminating the program should begiven, unless one is convinced the patient will finish
the full course. If he or she has completed less than six months at the time ofthe lapse
of more than one month, therapy should be restarted with the goal of completing six
subsequent months oftherapy. In particularly recalcitrant patients, a goal ofa total of
six months' therapy, counting both the months before and months after the lapse, may
be considered enough [52].
CandidatesforProphylaxis
Deciding what drugs to use for prophylaxis may be easier than determining who
should be treated. The most severe adverse effect associated with isoniazid is hepatitis
[55]. Riskforhepatotoxicity increaseswith age,concomitant useofrifampin, consump-
tion of alcohol on a daily basis, and the presence of liver disease [2]. Persons who
rapidly acetylate isoniazid also are at increased risk. For these reasons, isoniazid
prophylaxis is recommended for tuberculin reactors (Table 1) less than 35 years old
and for reactorsofany agewho (1) haverecentlybeen in contactwith an activecase, (2)
have converted from known negative reaction to positive within the last two years [52],
(3) have had tuberculosis in the past with no or inadequate treatment, (4) have a chest
radiograph showing stable lesions consistent with tuberculosis (lesions that have not
changed after three months' treatment for active tuberculosis, or (5) have extenuating
clinical problems such as silicosis, diabetes mellitus, or compromised immune systems.
Isoniazid prophylaxis is safe even in the very elderly when properly monitored [56].
Careful instruction on signs and symptoms of hepatitis should be given, and drug
toxicity followed on clinical rather than laboratory bases in uncomplicated patients
younger than 35 years of age. Fulminant, fatal hepatitis occurs only when isoniazid is
continued despite clinical evidence ofhepatitis.
576MYCOBACTERIUM TUBERCULOSIS TODAY 577
SUMMARY
In summary, the face of tuberculosis in the United States is changing. Increases in
the numbers of immigrants, elderly people, and immunosuppressed persons, whether
from administration of necessary medications or because of conditions such as lym-
phatic malignancies or HIV infections, have caused a revision in classification of skin
test reactors. New diagnostic laboratory techniques are available or on the horizon.
Studies on the efficacyofshorter courses ofchemotherapy forclinical tuberculosis have
demonstrated that treatment for as short a period as six months produces outcomes
comparable to those obtained with longer courses. Successful treatment of clinically
apparent tuberculosis and oftuberculous infection is more likely ifpatient compliance
can be assured. Measures should be adopted to enhance compliance with medication
regimens regardless oflength oftreatment.
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